Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma

Next Previous
Trial Profile

Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 04 Jun 2024 Preliminary results assessing the efficacy and safety of anlotinib combined with sintilimab as first-line treatment in patients with advanced nccRCC, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
  • 06 Jun 2023 Preliminary results (n=18) assessing efficacy and safety of anlotinib as first-line treatment in patients with advanced nccRCC presented at the 59th Annual Meeting of the American Society of Clinical Oncology
  • 08 Feb 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top